*ST目药(600671) - 2018 Q1 - 季度财报

Financial Performance - Operating revenue surged by 280.98% to CNY 90,371,921.11 year-on-year[7] - Net profit attributable to shareholders was a loss of CNY 1,882,756.79, an improvement from a loss of CNY 3,093,781.70 in the same period last year[7] - Cash flow from operating activities was CNY 34,276,082.11, a significant recovery from a negative cash flow of CNY 10,103,981.15 in the previous year[7] - The weighted average return on net assets improved to -2.8453% from -5.3877% year-on-year[7] - Basic and diluted earnings per share were both -CNY 0.0155, an improvement from -CNY 0.0254 in the same period last year[7] - The net loss for the period was reported at ¥-132,229,123.43, compared to ¥-130,346,366.64 at the beginning of the year, indicating a slight increase in losses[21] - Total operating revenue for Q1 2018 was CNY 90,371,921.11, a significant increase from CNY 23,720,706.06 in the same period last year, representing a growth of approximately 279.5%[26] - The net profit for Q1 2018 was a loss of CNY 1,607,169.74, an improvement from a loss of CNY 3,181,890.89 in Q1 2017, reflecting a reduction in losses of approximately 49.5%[27] Assets and Liabilities - Total assets increased by 11.74% to CNY 482,065,558.74 compared to the end of the previous year[7] - The company's total assets reached ¥482,065,558.74, up from ¥431,405,608.68, representing a growth of about 11.7%[21] - Total current assets increased to ¥257,224,338.46 from ¥207,068,832.58, representing a growth of approximately 24.2%[19] - Total liabilities increased to ¥386,444,179.25 from ¥334,177,059.45, which is an increase of approximately 15.6%[21] - The total equity attributable to shareholders decreased to ¥65,229,114.74 from ¥67,111,871.53, a decline of approximately 2.8%[21] Cash Flow and Investments - The company's cash and cash equivalents increased by 89.63% to ¥77,038,911.32, primarily due to the recovery of ¥9 million from the disposal of Tian Gong Shang Xia and a government reward of ¥36.93 million received by a subsidiary[13] - Cash received from sales of goods and services in Q1 2018 was CNY 86,016,459.63, compared to CNY 19,534,924.56 in Q1 2017, marking an increase of approximately 339.5%[32] - Operating cash inflow totaled CNY 17,329,307.23, an increase from CNY 10,216,485.98 in the previous period, representing a growth of approximately 69.5%[36] - Net cash flow from operating activities was negative at CNY -4,177,151.24, an improvement from CNY -9,137,359.82 in the previous period[36] - Cash inflow from investment activities was CNY 9,000,000.00, slightly down from CNY 11,500.00 in the previous period[37] - Net cash flow from investment activities was CNY 8,853,474.00, a recovery from CNY -7,115,108.90 in the previous period[37] - Cash inflow from financing activities reached CNY 81,680,000.00, up from CNY 20,130,000.00 in the previous period[37] - Net cash flow from financing activities was positive at CNY 795,161.67, an improvement from CNY -1,131,560.41 in the previous period[37] Shareholder Information - The top shareholder, Great Wall Film and Television Culture Group, holds 24.63% of the shares[11] Market and Product Development - The company has not disclosed any new product or technology developments in this report[7] - There are no announcements regarding market expansion or mergers and acquisitions in this quarter[7] - The company is actively pursuing market expansion and product development, having obtained the new GMP certification for its eye drop production line, which will enhance product quality and production capacity[15] Other Financial Metrics - The company reported non-operating income of CNY 413,061.48, primarily from government subsidies[9] - Accounts receivable rose by 20.22% to ¥58,929,105.93, mainly driven by increases from subsidiaries Huangshan Tianmu and Tianmu Biological, contributing ¥4.4 million and ¥3.7 million respectively[13] - Operating costs increased by 330.61% to ¥60,522,055.00, reflecting the rise in sales revenue[14] - The company completed the transfer of real estate and land use rights for ¥65 million, enhancing asset efficiency and focusing on core business operations[15] - The intangible assets increased by 559.36% to ¥51,900,489.50, primarily due to the acquisition of land use rights by a subsidiary[13] - Short-term borrowings decreased by 39.31% to ¥52,500,000.00, reflecting a reduction in the parent company's short-term debt[14] - The company reported a significant increase in other receivables, rising to ¥13,126,509.83 from ¥1,874,343.21, which is an increase of about 600.5%[19] - Sales expenses for Q1 2018 were CNY 15,214,916.55, significantly higher than CNY 3,209,853.92 in Q1 2017, representing an increase of approximately 373.5%[26] - Management expenses for Q1 2018 were CNY 13,051,816.33, compared to CNY 7,640,948.94 in the same period last year, reflecting an increase of about 70.5%[26]